Bullous Pemphigoid Market Set to Grow Rapidly Through 2035 – BIS Research

What Is Bullous Pemphigoid? 

Bullous pemphigoid is a chronic autoimmune blistering skin disease typically affecting older adults (mostly age 60–80), characterized by tense bullae due to autoantibody-mediated attack on dermo‑epidermal junction proteins such as BP180 and BP230. Diagnosis relies on clinical presentation combined with immunofluorescence microscopy techniques. Treatment modalities range from topical or systemic corticosteroids to immunosuppressants, antibiotics plus nicotinamide, and for refractory cases biologic agents like rituximab and IVIg. 

What Is the Market Outlook? 

• Therapy Adoption: While corticosteroids and immunosuppressants remain foundational, new biologics such as dupilumab, nomacopan, bertilimumab, avdoralimab, benralizumab, and AKST4290 are moving through late-stage pipelines to reshape treatment paradigms. 
• Regional Expansion: The US leading in largest patient pool and revenue, followed by growing adoption in Europe and Japan. 
• Competitive & Clinical Focus: Many biotech and pharma players including Regeneron/Sanofi, Akari Therapeutics, Immune Pharmaceuticals, Innate Pharma, AstraZeneca, Grifols, iCo Therapeutics, and Nihon Pharma are actively developing late-stage therapies for bullous pemphigoid. 

How Fast Is the Market Growing? 

The bullous pemphigoid market is witnessing sustained and robust growth momentum, driven by increasing adoption of biologic therapies and rising awareness among healthcare providers. Analysts forecast significant expansion across key developed and emerging regions, supported by improvements in diagnostic techniques, expanded clinical trial pipelines, and new product launches. 

This upward trajectory is also shaped by a growing pool of aging patients and an urgent need for steroid-sparing therapies that offer long-term remission with fewer side effects. With more biologics advancing through clinical stages and regulatory frameworks becoming more adaptive, the market outlook remains highly favorable throughout the forecast period. 

How Will This Report Help You? 

Planning to Enter the Market? 

• Review regional and country-level epidemiology and diagnosed prevalent cases across US, EU‑5, UK, Japan, and potentially emerging APAC markets. 
• Understand the adoption landscape: corticosteroids, immunosuppressants, topical agents, and pipeline biologics. 

Analyzing the Competitive Landscape? 

• Track key players: Regeneron/Sanofi (dupilumab), Akari (nomacopan), iCo Therapeutics (bertilimumab), Innate Pharma (avdoralimab), AstraZeneca (benralizumab), Grifols (AKST4290). 
• Evaluate pipeline maturity, clinical trial phases, partnerships, licensing, and approval outlook. 

Seeking R&D Insights? 

• Explore mechanism-of-action diversity: anti‑CD20, complement inhibitors, cytokine blockade, mast-cell stabilizers, IVIg, etc. 
• Monitor diagnostic innovation including ELISA, immunofluorescence, biomarker assays. 

Interested in Regional Market Trends? 

• Understand differential diagnosis rates, reimbursement policies, and adoption timelines across major markets and how they compare with underserved regions.

Download the Full TOC or Book a Preview   

What Technologies Are Transforming the Market? 

• Monoclonal Antibodies & Biologics: Dupilumab, rituximab (anti‑CD20), complement inhibitors (nomacopan), anti‑CCR4 agents, Fasenra (benralizumab). 
• Immunomodulatory Therapies: IVIg, TNF‑α antagonists (e.g. etanercept), methotrexate, azathioprine  
• Diagnostic Tools: Skin biopsy with direct and indirect immunofluorescence, ELISA assays for BP antigens. 
• Digital & Telemedicine Aids: AI-assisted diagnosis, treatment adherence tracking via digital tools, and potentially companion diagnostics. 

Unlock Critical Insights with Surgical Procedure Database   

Discover BIS Research Surgical Procedure Volume Database your key to real-world, country-level procedural insights across MedTech.      

What’s Driving Demand, Opportunities, and Barriers? 

Demand Drivers 

• Surge in autoimmune diseases and aging populations globally. 
• Unmet need: lack of specific approved drugs especially in US and EU heightens value proposition of pipeline therapies. 
• Increased disease awareness and diagnostic improvements. 

Opportunities 

• Launch of novel biologics with better safety and efficacy. 
• Adoption of precision therapies and personalized approaches. 
• Expansion into high-growth emerging markets with growing healthcare infrastructure. 

Challenges 

• Side effects and complications associated with systemic corticosteroids and broad immunosuppressants. 
• Delayed diagnosis and low awareness among clinicians. 
• High therapy cost, stringent reimbursement policies, complex regulatory pathways. 
• Limited disease knowledge and polypharmacy concerns in older patients  

Key players  

•    Sanofi 

•    Regeneron Pharmaceuticals 

•    Amgen Inc. 

•    Johnson & Johnson 

•    Chugai Pharmaceutical 

•    Novartis AG 

•    F. Hoffmann-La Roche Ltd 

•    Teva Pharmaceutical Industries Ltd 

•    Astellas Pharma Inc. 

•    Sun Pharmaceutical Industries Ltd 

•    Others 

Strategic Developments 

• Clinical Trials & Approvals: Several biologics in mid‑ to late‑stage development (dupilumab, nomacopan, bertilimumab, avdoralimab, benralizumab, AKST4290) aiming to secure regulatory approvals across major markets. 
• Collaborations & Licensing: Partnerships between biotech and large pharma to advance pipeline candidates. 
• Diagnostic Innovation: Greater integration of immunofluorescence diagnostics and ELISA assays to support earlier detection and patient stratification. 

Download the complete TOC now! 

Case Study 

While public detailed case‑study data is limited, adoption of biologic agents like rituximab and dupilumab in real‑world clinical settings has shown improved remission rates and steroid‑sparing effects suggesting significant long‑term benefits and opening case bases demonstrating value in resistant or relapsed bullous pemphigoid. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Next-Generation Intervention Cardiology Market 

Integrated LED Light Source Endoscope Market 

Flow Cytometry Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686  

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc